Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

137.60 +0.60 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,387,274
Open 136.00
Bid (Size) 136.75 (3)
Ask (Size) 137.60 (2)
Prev. Close 137.00
Today's Range 134.73 - 138.07
52wk Range 62.55 - 170.47
Shares Outstanding 383,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting drug-resistant pathogens. This partnership supports Lilly's commitment to... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+22.31%
+22.31%
1 Month
-10.18%
-10.18%
3 Month
+28.11%
+28.11%
6 Month
+41.37%
+41.37%
1 Year
+14.28%
+14.28%

More News

Read More
Moderna's Options: A Look at What the Big Money is Thinking
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $900 Today
Via Benzinga
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
S&P 500, Nasdaq Lurking Below Record Highs
Via Talk Markets
Topics Stocks
Exposures US Equities
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Via ACCESSWIRE
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
The RBA Kept Interest Rates On Hold And Remained Hawkish
Via Talk Markets
OpenAI And Color Health Develop AI-Driven Cancer Care Solutions: Report
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Moderna Just Gave Investors Another Reason to Buy the Stock
Via The Motley Fool
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Via ACCESSWIRE
7 Struggling Stocks to Sell Before July 2024
Via InvestorPlace
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
Via InvestorPlace
Exposures Product Safety
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
What's Going On With Moderna Stock Monday?
Via Benzinga
Exposures COVID-19
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
Via Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
Via The Motley Fool
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
3 Reasons to Buy Moderna Stock
Via The Motley Fool
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Via Benzinga
Exposures COVID-19 Product Safety
5 Stocks Propelling S&P 500 To 25th Record High
Via Talk Markets
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.